Researchers at Queen’s University of Belfast and collaborators have developed a DNA vaccine against high-grade serous ovarian cancer. The vaccine encodes PRAME, which the researchers found to be upregulated in several cohorts of patients with the malignancy.
Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel disease in animal models.
Sillajen Inc. has recently presented data regarding their threonine tyrosine kinase (TTK) and Polo-like kinase 1 (PLK1) dual inhibitor BAL-0891 as a therapeutic approach for acute myeloid leukemia (AML) treatment. The compound was tested both in vitro and in vivo in the preclinical setting.
Synfini Inc. and O2nix Bio have established a strategic collaboration to co-discover and develop novel drug candidates targeting FTSJ1, a tRNA-modifying enzyme implicated in metastatic cancer cell survival.
Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a positive opinion for orphan drug designation, confirming that DIAG-723 meets the criteria for designation as an orphan drug in the E.U.
Biomea Fusion Inc. has released preclinical findings from a 28-day weight loss study in obese nonhuman primates evaluating BMF-650, a next-generation oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA).
About 30%-40% of triple-negative breast cancers (TNBC) show HER2-low status and may benefit from the HER2-directed antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Ataxia-telangiectasia mutated (ATM) kinase plays a crucial role in double-strand break (DSB) repair response, thus inhibitors of ATM, such as AZD-1390, may enhance the effect of DSB inducers, resulting in DNA damage accumulation.
Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 1 diabetes, atherosclerosis, type 2 diabetes, obesity, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), hypertension, diabetic complications and coronary heart disease among others.
RSS
